FDA reclassification of Rapid Antigen flu testing

August 10, 2017

 

FDA reclassification of rapid flu antigen testing

Please join Frederick S. Nolte, Ph.D., D(ABMM), F(AAM), Professor and Vice Chair for Laboratory Medicine in the Department of Pathology and Laboratory Medicine, and Medical Director of Clinical Laboratories, Molecular Pathology Laboratory and Point-Care-Testing at the Medical University of South Carolina, as he shares his insight regarding the recent FDA reclassification of Rapid Antigen flu testing, and why it's an opportunity for lab leadership.

 

Previous Article
Engaging Your Team from Good to Great
Engaging Your Team from Good to Great

Join Josie Foranoce, B.S., MT ASCP, as she presents strategies on how to improve employee engagement and la...

Next Article
Redefining the Value of Diagnostics in a Changing Payment Environment
Redefining the Value of Diagnostics in a Changing Payment Environment

Please join Charles Mathews, Vice President, Boston Healthcare Associates, as he shares insights into how l...

×

LabLeaders.com has a new home. Tell us a bit about yourself.

Thank you!
Error - something went wrong!